L Keoki Williams1, Badri Padhukasahasram, Brian K Ahmedani, Edward L Peterson, Karen E Wells, Esteban González Burchard, David E Lanfear. 1. Center for Health Policy and Health Services Research (L.K.W., B.P., B.K.A., D.E.L.), Department of Internal Medicine (L.K.W., D.E.L.), Department of Public Health Sciences (E.L.P., K.E.W.), Henry Ford Health System, Detroit, Michigan 48202; and Departments of Medicine (E.G.B.) and Bioengineering and Therapeutic Sciences (E.G.B.), University of California, San Francisco, San Francisco, California 94143.
Abstract
CONTEXT: Metformin is considered first-line treatment for type 2 diabetes mellitus. However, little is known about its effects in African American individuals. OBJECTIVE: The objective of the study was to assess whether metformin's effect on glycemic control differs by race-ethnicity Design: Electronic health records were used to identify adults who had a diagnosis of diabetes, two or more fills of metformin, and two or more glycated hemoglobin (HbA1c) measurements. Pharmacy claims were used to estimate metformin exposure based on fill frequency and dose dispensed. Regression analyses modeled the relationship between metformin exposure and HbA1c levels. Analyses were stratified by race-ethnicity and baseline HbA1c values. SETTING: The study was conducted at a large health system in southeast Michigan. MAIN OUTCOME MEASURE: Differences in HbA1c levels while on metformin were measured. RESULTS: We identified 19 672 patients with diabetes taking metformin; 7429 were African American and 8783 were European American. Baseline HbA1c values in these two groups were 7.81% (61.8 mmol/mol) and 7.38% (57.1 mmol/mol), respectively. Compared with no use, metformin was associated with a 0.62% (6.8 mmol/mol) reduction in HbA1c; however, there was a significant difference by race-ethnicity (P < .001). Among African American individuals, metformin use was associated with a 0.90% (9.8 mmol/mol) reduction in HbA1c levels, whereas among European Americans, metformin was associated with a 0.42% (4.6 mmol/mol) reduction. Irrespective of baseline HbA1c, metformin use was associated with lower HbA1c levels in African American individuals. CONCLUSIONS: African American individuals appear to have a better glycemic response to metformin when compared with European Americans. Further studies are needed to determine whether this translates to commensurate reductions in diabetes complications.
CONTEXT: Metformin is considered first-line treatment for type 2 diabetes mellitus. However, little is known about its effects in African American individuals. OBJECTIVE: The objective of the study was to assess whether metformin's effect on glycemic control differs by race-ethnicity Design: Electronic health records were used to identify adults who had a diagnosis of diabetes, two or more fills of metformin, and two or more glycated hemoglobin (HbA1c) measurements. Pharmacy claims were used to estimate metformin exposure based on fill frequency and dose dispensed. Regression analyses modeled the relationship between metformin exposure and HbA1c levels. Analyses were stratified by race-ethnicity and baseline HbA1c values. SETTING: The study was conducted at a large health system in southeast Michigan. MAIN OUTCOME MEASURE: Differences in HbA1c levels while on metformin were measured. RESULTS: We identified 19 672 patients with diabetes taking metformin; 7429 were African American and 8783 were European American. Baseline HbA1c values in these two groups were 7.81% (61.8 mmol/mol) and 7.38% (57.1 mmol/mol), respectively. Compared with no use, metformin was associated with a 0.62% (6.8 mmol/mol) reduction in HbA1c; however, there was a significant difference by race-ethnicity (P < .001). Among African American individuals, metformin use was associated with a 0.90% (9.8 mmol/mol) reduction in HbA1c levels, whereas among European Americans, metformin was associated with a 0.42% (4.6 mmol/mol) reduction. Irrespective of baseline HbA1c, metformin use was associated with lower HbA1c levels in African American individuals. CONCLUSIONS: African American individuals appear to have a better glycemic response to metformin when compared with European Americans. Further studies are needed to determine whether this translates to commensurate reductions in diabetes complications.
Authors: Manel Pladevall; L Keoki Williams; Lisa Ann Potts; George Divine; Hugo Xi; Jennifer Elston Lafata Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Curt L Rohlfing; Hsiao-Mei Wiedmeyer; Randie R Little; Jack D England; Alethea Tennill; David E Goldstein Journal: Diabetes Care Date: 2002-02 Impact factor: 19.112
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Sami Hayek; Fabrizio Canepa Escaro; Assad Sattar; Steven Gamalski; Karen E Wells; George Divine; Brian K Ahmedani; David E Lanfear; Manel Pladevall; L Keoki Williams Journal: Am J Cardiol Date: 2012-12-04 Impact factor: 2.778
Authors: Daniel M Rotroff; Sook Wah Yee; Kaixin Zhou; Skylar W Marvel; Hetal S Shah; John R Jack; Tammy M Havener; Monique M Hedderson; Michiaki Kubo; Mark A Herman; He Gao; Josyf C Mychaleckyi; Howard L McLeod; Alessandro Doria; Kathleen M Giacomini; Ewan R Pearson; Michael J Wagner; John B Buse; Alison A Motsinger-Reif Journal: Diabetes Date: 2018-04-12 Impact factor: 9.461
Authors: Danthasinghe Waduge Badrajee Piyarathna; Akhila Balasubramanian; James M Arnold; Stacy M Lloyd; Balasubramanyam Karanam; Patricia Castro; Michael M Ittmann; Nagireddy Putluri; Nora Navone; Jeffrey A Jones; Wendong Yu; Vlad C Sandulache; Andrew G Sikora; George Michailidis; Arun Sreekumar Journal: J Clin Invest Date: 2019-03-28 Impact factor: 14.808
Authors: Maureen Sanderson; Loren Lipworth; Martha J Shrubsole; Shaneda Warren Andersen; Xiao-Ou Shu; Wei Zheng; Margaret K Hargreaves; William J Blot Journal: Cancer Causes Control Date: 2019-04-02 Impact factor: 2.506
Authors: Jung-Im Shin; Yingying Sang; Alex R Chang; Stephan C Dunning; Josef Coresh; Lesley A Inker; Elizabeth Selvin; Shoshana H Ballew; Morgan E Grams Journal: J Am Soc Nephrol Date: 2020-07-13 Impact factor: 10.121
Authors: Saira Khan; Jianwen Cai; Matthew E Nielsen; Melissa A Troester; James L Mohler; Elizabeth T H Fontham; Laura Farnan; Bettina F Drake; Andrew F Olshan; Jeannette T Bensen Journal: Cancer Causes Control Date: 2018-09-28 Impact factor: 2.506
Authors: Jeffrey F Scherrer; John E Morley; Joanne Salas; James S Floyd; Susan A Farr; Sascha Dublin Journal: Ann Fam Med Date: 2019-07 Impact factor: 5.166
Authors: Chen-Pin Wang; Donna M Lehman; Yui-Wing F Lam; John G Kuhn; Devalingam Mahalingam; Steven Weitman; Carlos Lorenzo; John R Downs; Elizabeth A Stuart; Javier Hernandez; Ian M Thompson; Amelie G Ramirez Journal: Cancer Prev Res (Phila) Date: 2016-03-29